Protocells and their use for targeted delivery of multicomponent cargos to cancer cells
| DWPI Title: Delivering cargo components e.g. proteins, peptides and antibodies to cancer cell, by providing protocell compound containing lipid bilayer encasing porous particle core, and mixing protocell compound with target cell |
| Abstract: Various embodiments provide materials and methods for synthesizing protocells for use in targeted delivery of cargo components to cancer cells. In one embodiment, the lipid bilayer can be fused to the porous particle core to form a protocell. The lipid bilayer can be modified with targeting ligands or other ligands to achieve targeted delivery of cargo components that are loaded within the protocell to a target cell, e.g., a type of cancer. Shielding materials can be conjugated to the surface of the lipid bilayer to reduce undesired non-specific binding. |
| Use: The method is useful for delivering cargo components to cancer cell (claimed). The cargo components are drugs, proteins, peptides, antibodies, nucleic acids, fluorescent dyes, inorganic nanoparticles, chemotherapeutic drugs, anticancer drugs and antibacterial agent. |
| Advantage: The method overcomes problem of solubility, stability, rapid clearing and lack of selectivity, in drugs, causes toxicity to normal cells and prevents dose escalation necessary to eradicate diseased cells, delivers component having enhanced permeability and retention, and simultaneously improves high targeting specificity and delivery efficiency, while avoiding nonspecific binding and entrapment by body's defence. |
| Novelty: Delivering cargo components to cancer cell, involves providing protocell compound comprising lipid bilayer encasing porous particle core, several types of cargo components arranged within porous particle core, targeting ligand attached to lipid bilayer, fusogenic ligand attached to lipid bilayer, and shielding material attached to lipid bilayer, and mixing protocell compound with the target cell such that the protocell compound is selectively bound to the target cell and internalized in the target cell induced by the targeting ligand. |
| Filed: 2/20/2015 |
| Application Number: US14627739A |
| Tech ID: SD 12305.3 |
| This invention was made with Government support under Contract No. DE-NA0003525 awarded by the United States Department of Energy/National Nuclear Security Administration. The Government has certain rights in the invention. |
| Data from Derwent World Patents Index, provided by Clarivate All rights reserved. Republication or redistribution of Clarivate content, including by framing or similar means, is prohibited without the prior written consent of Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license. |